anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clarithromycin tablets are given in combination with other drugs in adults as described below to eradicate H. pylori. The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.3)].

  


  * Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori.
  * Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. Regimens which contain clarithromycin tablets as the single antibacterial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting.
An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.
Cryopyrin-associated periotic syndrome (CAPS) is a rare autoinflammatory disease caused by genetic variants in innate immunity genes. Autoinflammatory diseases, including CAPS, mediate proinflammatory cytokines such as interleukin (IL)-1 and IL-18 and result in severe systemic inflammation. A gain-of-function mutation in the NLR family pyrin domain-containing 3 (NLRP3) gene, which encodes the protein cryopyrin, was identified to be responsible for CAPS in 2001, and since then several additional pathogenic mutations have been found. Moreover, other phenotypes have been identified based on severity and symptomatology, including familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease/chronic neurologic cutaneous articular syndrome. Prompt diagnosis of CAPS remains challenging, however, due to unspecific, extensive clinical signs, and delayed diagnosis and treatment targeting IL-1 lead to multiorgan damage. Another factor complicating diagnosis is the existence of somatic mosaic mutations in the NLRP3 gene in some cases, resulting in symptoms and clinical courses that are atypical. The frequency of somatic mosaic mutations in CAPS was estimated to be 19% in a systematic review. Psoriasis is a chronic inflammatory skin disease that affects ∼3% of the global population. Although no reports have shown complication between CAPS and psoriasis, these diseases have several similarities and potential relationships, for instance activation of T helper 17 cells in the dermis and increased NLRP3 gene expression in psoriatic skin compared with normal skin. Here, we report a case of CAPS due to a somatic mosaic mutation with recurrent circinate erythematous psoriasis.
Anti-anaemia preparations are obtained by treatment of crude aqueous or alcoholic extracts with an adsorbing agent in a neutral or slightly acid medium and separation of the active substance from the adsorbate by treatment with a dilute alkaline solution.  Suitable adsorbents are fuller's earth, bentonite, silica gell, active charcoal.  According to an example minced liver is extracted with water and 10 ccs. of concentrated hydrochloric acid and 40 grams of fuller's earth are added for each litre of filtrate.  The adsorbent is separated, washed and suspended in a mixture of water, pyridine and methylalcohol.  The mixture is filtered and concentrated at a low temperature, residual pyridine being removed by ether, and the extract-reconcentrated.  Protein substances may be removed from the product by the addition of alcohol, filtering and reconcentrating.
A lay patient navigator will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
PURPOSE: To obtain the subject new compound, a specific cephem compound, having a wide range of antimicrobial activity, presenting excellent antimicrobial action on methicillin-resistant Staphylococcus aureus(MRSA) and Pseudomonas bacteria, thus useful as e.g. an antimlcrobial agent. CONSTITUTION: This new cephem compound (ester, salt) is expressed by formula I [R<1> is a (protected) amino; R<2> is H car a group linked via a carbon atom; A<+> is a substituted group of e.g. formula II (B is a six-membered aromatic heterocycle with one or two heteroatoms being N; R<3> is a hydrocarbon)]. This compound has excellent antimicrobial effect on a wide range of Gram-positive and Gramnegative bacteria, esp. Staphylococcus aureus, MRSA and Pseudomonas bacteria, etc., therefore being useful as e.g. an antimicrobial agent. This compound is obtained by reaction of a 7-amino-3-cephem-4-carboxylic acid compound of formula III with a 1,2,4-thiadiazol-3-yl-3-iminoacetic acid derivative of formula IV.
Aspects of the present disclosure are directed to immune cells comprising polynucleotides encoding genetically engineered receptors ( e.g. , chimeric antigen receptors, T-cell receptors) and having anti-CD20 antibodies (or fragments thereof) attached to their surface. Certain aspects are directed to preactivated and/or expanded natural killer cells having anti-CD20 antibodies (or fragments thereof) attached to their surface. Also disclosed are compositions comprising such cells, and methods for using such compositions to treat an individual having CD20-positive cancer. Further aspects encompass methods for cell preparation comprising culturing natural killer cells with cytokines ( e.g. , IL-12, IL-15, and/or IL-18) and incubating the cells with an anti-CD20 antibody.
A vaccine for use against theileriasis of cattle comprises lymphoid cells of cattle invaded with the schizonts of the attenuated strain of Theileria annulata KTA No. 7. The vaccine is prepared by attenuation of an epizootic strain of Theileria annulata CY-1 No. 6 isolated from an invaded tick Hyalomma detritum. The strain is attenuated by cultivating it on a lymphoid cell culture of cattle for 20-100 days. The resultant product is a suspension of the lymphoid cells invaded with the schizonts of the strain Th. annulata KTA No. 7.
Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
Participants in group A will take part in 4 weeks of treatment with 5 sessions per week. Each session will involve sham repetitive transcranial magnetic stimulation (rTMS). Sham rTMS will be delivered at 10 Hz, 2004 pulses targeting the leg representation of the primary motor cortex. Participants will hear and experience the clicking but will not be provided with any stimulation. Sham rTMS will take approximately 11.5 minutes.
Obstructive sleep apnea (OSA) is a sleep disorder characterized by a cessation or significant decrease in airflow during sleep. According to a recent study, OSA may impact over 1 billion individuals worldwide. In Thailand, the prevalence of snoring in children is 6.9-8.5%, while the prevalence of OSA in children is 0.7-1.3%. Moreover, OSA affects 15.4% of Thai male adults and 6.3% of Thai females. Untreated OSA can lead to daytime sleepiness, decreased productivity, increased motor vehicle accidents, and worsening hypertension, atrial fibrillation, and stroke. Oral appliances, upper airway surgery, and continuous positive airway pressure (CPAP) devices are available as treatment alternatives.

CPAP is the preferred therapy and has high effectiveness at all levels of OSA severity. It acts as a pneumatic splint to maintain upper airway patency during sleep, preventing the soft tissues from collapsing. Through this mechanism, it effectively eliminates the apneas and/or hypopneas, decreases the arousals, and normalizes the oxygen saturation. However, the patient's compliance continues to be an issue. Failure of CPAP therapy may occur in up to 25% to 50% of patients, with patients typically discontinuing therapy within the first 2 to 4 weeks of treatment and 91% of patients discontinuing CPAP therapy within the first three years of therapy.

According to the clinical guidelines of the American Academy of Sleep Medicine, all potential PAP titration candidates should receive adequate PAP education, hands-on demonstration, careful mask fitting, and acclimatization prior to titration. Acclimatization is a technique used to familiarize patients with PAP therapy for compliance.

One of the main contributors to CPAP therapy failure is difficulty falling asleep. To aid in the machine's adaptation, hypnotic medicine was administered. Sedative medications now came in a variety of categories. Non-benzodiazepines sometimes referred to as Z-drugs, are among those with the beneficial characteristics of not deteriorating OSA severity, not contributing to drug addiction, possessing a rapid onset, and exhibiting fewer adverse consequences. Zolpidem, eszopiclone and zaleplon are included in this drug class. According to a previous meta-analysis, eszopiclone greatly facilitated the use of CPAP. However, up until now limited research on zolpidem and zaleplon was conducted. This study aims to evaluate the effect of zolpidem on CPAP compliance in OSA patients as compared to a placebo.
Background: Most children and adolescents with cancer experience acute pain, and many experience longer-lasting chronic pain, negatively impacting health-related quality of life and resulting in long-term morbidity. Digital apps can aid in enhancing pain assessment and management by offering children and adolescents with cancer an accessible tool to describe their pain as a multifaceted biopsychosocial construct. Pain Squad is a useable, acceptable, and psychometrically sound multidimensional cancer pain assessment app for children and adolescents with cancer. This project aimed to evaluate the capacity to implement Pain Squad into routine pediatric oncology practice. Method: Nurse champions were asked to prescribe the Pain Squad app to patients over a 6-month implementation period. After the implementation period, we conducted audiorecorded, semistructured interviews with nurse champions to investigate the facilitators and barriers related to nurses' experiences with implementing Pain Squad. Results: The facilitators and barriers to Pain Squad implementation were organized into four overarching Consolidated Framework for Implementation Research (CFIR)-related themes: (a) characteristics of the Pain Squad app; (b) clinic setting and its context; (c) nurse implementation champions; and (d) the process of implementing Pain Squad into clinical practice. Conclusions: Interviewed nurses believed Pain Squad had the potential to improve child cancer pain care, but barriers to everyday use were evident, described in relation to the internal setting, especially the lack of compatibility between app prescription and current nurse workflows. The use of CFIR to map identified implementation facilitators and barriers can formally support the recognition of factors that may boost the chances of successful uptake.
BACKGROUND: Perineural invasion (PNI) has been used as an important pathological indicator and independent prognostic factor for patients with rectal cancer (RC). Preoperative prediction of PNI status is helpful for individualized treatment of RC. Recently, several radiomics studies have been used to predict the PNI status in RC, demonstrating a good predictive effect, but the results lacked generalizability. The preoperative prediction of PNI status is still challenging and needs further study.
AIM: To establish and validate an optimal radiomics model for predicting PNI status preoperatively in RC patients.
METHODS: This retrospective study enrolled 244 postoperative patients with pathologically confirmed RC from two independent centers. The patients underwent pre-operative high-resolution magnetic resonance imaging (MRI) between May 2019 and August 2022. Quantitative radiomics features were extracted and selected from oblique axial T2-weighted imaging (T2WI) and contrast-enhanced T1WI (T1CE) sequences. The radiomics signatures were constructed using logistic regression analysis and the predictive potential of various sequences was compared (T2WI, T1CE and T2WI + T1CE fusion sequences). A clinical-radiomics (CR) model was established by combining the radiomics features and clinical risk factors. The internal and external validation groups were used to validate the proposed models. The area under the receiver operating characteristic curve (AUC), DeLong test, net reclassification improvement (NRI), integrated discrimination improvement (IDI), calibration curve, and decision curve analysis (DCA) were used to evaluate the model performance.
RESULTS: Among the radiomics models, the T2WI + T1CE fusion sequences model showed the best predictive performance, in the training and internal validation groups, the AUCs of the fusion sequence model were 0.839 [95% confidence interval (CI): 0.757-0.921] and 0.787 (95%CI: 0.650-0.923), which were higher than those of the T2WI and T1CE sequence models. The CR model constructed by combining clinical risk factors had the best predictive performance. In the training and internal and external validation groups, the AUCs of the CR model were 0.889 (95%CI: 0.824-0.954), 0.889 (95%CI: 0.803-0.976) and 0.894 (95%CI: 0.814-0.974). Delong test, NRI, and IDI showed that the CR model had significant differences from other models (P < 0.05). Calibration curves demonstrated good agreement, and DCA revealed significant benefits of the CR model.
CONCLUSION: The CR model based on preoperative MRI radiomics features and clinical risk factors can preoperatively predict the PNI status of RC noninvasively, which facilitates individualized treatment of RC patients.
The invention relates to a diagnosis and treatment integrated bovine serum albumin anticancer nanoparticle and a preparation method thereof. The particle comprises bovine serum albumin, rare earth metal ion and anticancer drug, wherein the rare earth metal ion and bovine serum albumin form nanoparticle with imaging function through coordination, the anticancer drug is immobilized on the nanoparticle and is bound to the rare earth metal ion coordination site that interacts with bovine serum albumin. Compared with the prior art, according to the invention, bovine serum albumin solution with certain concentration and rare earth metal ion solution form a compound particle through coordination. The structure and morphology of the compound particle can be regulated by changing the concentration of the two solutions to improve the particle performance. In addition, an element (rare earth metal ion) with MRI effect is introduced at the coordination site of the system. Compared with the traditional nanoparticle, the preparation method has the advantages of flexible and easily controllable regulation, and good repetitiveness, and the obtained nanoparticle has excellent properties.
A total of 9 dose groups are expected to be evaluated in Phase Ia: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 6 mg/kg, and 10 mg/kg. One subject will be enrolled in the starting dose group of 0.03 mg/kg (if any ≥ Grade 2 dose-related adverse event is observed in this group during the DLT observation period, the group will be changed to the "3 + 3" method), and 3 or 6 subjects will be enrolled in each of other dose groups. The first 2 subjects in the same dose group shall receive the first dose at an interval of at least 48 hours to avoid acute hypersensitivity reactions, and the specific interval shall be determined by the investigator based on the safety assessment of subjects in the previous dose group. Ultimately, the sponsor and the investigator will determine whether an increase in dose group or in a specific fixed dose is required according to the actual situation of the trial.
The invention discloses an external tincture for treating wind-cold-dampness arthralgia. The external tincture is scientific and reasonable in compatibility of prescription, safe and convenient to use, and stable in curative effect. The external tincture has the effects of relieving swelling and pain, promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness, and warming channels and expelling cold, has the characteristics of being less in dosage, and fast and lasting in curative effect, and is mainly used for treating various pain disorders caused by cold, dampness and rheumatism. In the prescription, raw monkshood, spinyleaf pricklyash root, frankincense, periploca forrestii schltr and gaultheria yunnanensis are used for stretching the muscles and activating blood, expelling cold and dredging collaterals, relieving swelling and pain, and warming channels and expelling cold; cinnamon, borneol and shanwei (Chinese character) are used for tonifying fire and helping yang, clearing heat for resuscitation, and cooling blood and relieving pain; propolis is more amazing, can generate complicated chemical reaction after being mixed, soaked and dissolved together with the traditional Chinese medicines, and has the effects of resisting bacteria and diminishing inflammation, and promoting liquid absorption. The propolis is not dissolved into water, so that a layer of hidden protecting film can be quickly formed on a skin surface after the fairy tincture for chilling to the bone and relieving pain is painted. Thus, the pharmaceutical effect of relieving pain can be better developed.
Sorafenib, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate, USP has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate. The molecular formula of sorafenib tosylate, USP is C21H16ClF3N4O3.C7H8O3S and the molecular weight of sorafenib tosylate, USP is 637.03 grams/mole. Its structural formula is:

Sorafenib tosylate, USP is a white or slightly yellowish or brownish powder. Sorafenib tosylate, USP is soluble in polyethylene glycol 400, slightly soluble in ethanol, and practically insoluble in aqueous media (i.e. water) and in heptane. 

Sorafenib tablets, USP for oral use are supplied as film-coated tablets containing 200 mg of sorafenib equivalent to 274 mg sorafenib tosylate, USP and the following inactive ingredients: croscarmellose sodium, hypromellose, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium lauryl sulphate, talc and titanium dioxide. 

FDA approved dissolution test specifications differ from USP.
The efficacy of pregabalin for the management of neuropathic pain associated with spinal cord injury was established in two double-blind, placebo-controlled, multicenter studies. Patients were enrolled with neuropathic pain associated with spinal cord injury that persisted continuously for at least three months or with relapses and remissions for at least six months. A total of 63% of patients completed study 1 and 84% completed study 2. The patients had a minimum mean baseline pain score of greater than or equal to 4 on an 11-point numerical pain rating scale ranging from 0 (no pain) to 10 (worst possible pain). The baseline mean pain scores across the two studies ranged from 6.5 to 6.7. 

Patients were allowed to take opioids, non-opioid analgesics, antiepileptic drugs, muscle relaxants, and antidepressant drugs if the dose was stable for 30 days prior to screening. Patients were allowed to take acetaminophen and nonsteroidal anti-inflammatory drugs during the studies. 

Study SCI 1: This 12-week, randomized, double-blind, parallel-group, multicenter, flexible dose (150 to 600 mg/day) study compared pregabalin with placebo. The 12-week study consisted of a 3- week dose adjustment phase and a 9-week dose maintenance phase. Treatment with pregabalin 150 to 600 mg/day statistically significantly improved the endpoint weekly mean pain score, and increased the proportion of patients with at least a 30% and 50% reduction in pain score from baseline. The fraction of patients achieving various levels of improvement in pain intensity from baseline to Week 12 is presented in Figure 11. Some patients experienced a decrease in pain as early as week 1, which persisted throughout the study.

Figure 11: Patients Achieving Various Levels of Improvement in Pain Intensity – Study SCI 1

Study SCI 2: This 16-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter, flexible dose (150-600 mg/day, in increments of 150 mg) study compared the efficacy, safety and tolerability of pregabalin with placebo. The 16-week study consisted of a 4- week dose adjustment phase and a 12-week dose maintenance phase. Treatment with pregabalin statistically significantly improved the endpoint weekly mean pain score, and increased the proportion of patients with at least a 30% and 50% reduction in pain score from baseline. The fraction of patients achieving various levels of improvement in pain intensity from baseline to week 16 is presented in Figure 12. Some patients experienced a decrease in pain as early as week 1, which persisted throughout the study.

Figure 12: Patients Achieving Various Levels of Improvement in Pain Intensity – Study SCI 2
Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).